interferon
ifn
known
import
direct
antivir
antibacteri
effect
well
potent
modulatori
effect
adapt
immun
respons
via
induct
hundr
ifnstimul
gene
isg
newest
discov
class
ifn
ifn
lambda
ifnl
famili
four
member
ifnl
receptor
consist
heterodim
alpha
subunit
beta
subunit
ubiquit
express
wherea
express
restrict
interestingli
highli
express
lung
epitheli
cell
alveolar
macrophag
viru
seen
pattern
recognit
receptor
found
macrophag
epitheli
cell
ifnl
gene
express
stimul
via
variou
signal
pathway
lead
increas
circul
interact
ifnl
receptor
express
lung
intestin
liver
cell
via
jakstat
signal
cascad
induc
interferon
stimul
gene
turn
influenc
viral
replic
seri
singl
nucleotid
polymorph
snp
gene
region
describ
associ
variabl
gene
express
variabl
viral
bacteri
infect
may
lead
signific
differ
subsequ
immun
respons
thu
variabl
clinic
outcom
immunemodulatori
antitumorigen
effect
induc
viral
infect
viral
infect
play
import
role
exacerb
asthma
copd
reduc
interferon
activ
respiratori
syncyti
viru
infect
link
later
develop
asthma
children
mechan
virusinduc
exacerb
copd
welldefin
recent
role
ifnl
exacerb
asthma
explor
howev
data
avail
regard
effect
polymorph
exacerb
clinic
outcom
copd
copd
patient
expos
rhinoviru
consist
show
trend
toward
less
ifnl
express
bronchoalveolar
lavag
fluid
anim
model
shown
ifnl
play
role
viral
influenza
coronaviru
rotaviru
modul
hypothes
patient
copd
snp
gene
impact
clinic
outcom
exacerb
might
associ
circul
marker
inflamm
tissu
remodel
therefor
aim
explor
polymorph
circul
associ
occurr
exacerb
copd
allcaus
mortal
multin
multicent
prospect
longitudin
observ
cohort
studi
patient
clinic
stabl
exacerb
copd
patient
stabl
state
copd
gold
ii
iv
enrol
observ
prospect
trial
promisecopd
wwwcontrolledtrialscom
identifi
studi
detail
publish
previous
current
nest
biomark
studi
patient
consecut
recruit
follow
european
hospit
pneumolog
depart
novemb
octob
fig
detail
inclus
exclus
criteria
previous
publish
analys
data
patient
complet
first
monthfollowup
studi
serum
sampl
visit
avail
use
serum
sampl
stabl
phase
first
episod
exacerb
copd
patient
physic
examin
perform
vital
sign
regist
detail
histori
obtain
spirometri
walk
test
perform
follow
american
thorac
societi
guidelin
one
twoyear
followup
stabl
phase
includ
seri
outcom
marker
determin
previous
publish
addit
patient
treat
infectiontrigg
exacerb
copd
schedul
followup
four
week
postexacerb
onset
acut
exacerb
defin
acut
sustain
worsen
dyspnoea
cough
andor
sputum
beyond
normal
daytoday
variat
patient
underli
copd
sever
exacerb
defin
exacerb
requir
hospitalis
total
age
gender
unmatch
healthi
control
includ
studi
studi
observ
studi
without
specif
intervent
genotyp
serum
level
retrospect
determin
impact
treatment
decis
studi
approv
respect
particip
local
irb
center
ethikkommiss
beider
basel
medic
ethic
committe
amphia
ziekenhui
medic
ethic
committe
north
holland
klinicki
centar
srbije
eticki
odbor
clinic
research
ethic
committe
german
tria
pujol
hospit
medizinisch
hochschul
hannov
ethikkommiss
ethic
committe
hospit
clinic
barcelona
ethic
committe
policlinico
milan
ethic
committe
greec
patient
provid
written
inform
consent
serum
level
determin
stabl
phase
exacerb
copd
commerci
avail
sandwich
immunoassay
elisa
kit
show
crossreact
human
duoset
elisa
r
system
minneapoli
mn
usa
use
accord
manufactur
instruct
assay
linear
rang
detect
pgml
two
common
snp
gene
region
determin
previous
describ
distribut
minor
major
allel
genotyp
compar
previou
public
european
popul
previous
describ
serum
level
fragment
collagen
type
iii
fragment
collagen
type
vi
proform
collagen
type
iii
proform
collagen
type
vi
measur
nordic
bioscienc
assay
accord
manufactur
instruct
procalcitonin
copeptin
proadrenomedullin
adm
atrial
natriuret
polypeptid
anp
measur
previous
describ
differ
dichotom
variabl
evalu
use
chisquar
test
fischer
exact
test
appropri
normal
distribut
paramet
analyz
use
student
ttest
equal
mean
continu
nonnorm
distribut
paramet
evalu
use
nonparametr
mannwhitney
u
test
kruskalw
test
appropri
detect
level
sampl
assign
valu
pgml
lowest
detect
valu
assay
use
studi
kaplan
meier
curv
creat
determin
surviv
within
year
overal
surviv
occurr
exacerb
occurr
sever
exacerb
logrank
test
use
compar
differ
surviv
curv
statist
packag
social
scienc
program
ssp
inc
version
window
use
test
twotail
pvalu
consid
signific
result
express
mean
standard
deviat
median
interquartil
rang
unless
otherwis
state
distribut
snp
adher
hardi
weinberg
equilibrium
test
deviat
equal
valu
less
repres
signific
level
degre
freedom
therefor
null
hypothesi
popul
hardyweinberg
frequenc
reject
common
genotyp
tt
follow
tg
gg
tabl
patient
gg
genotyp
significantli
shorter
time
sever
exacerb
patient
tt
tg
genotyp
fig
p
significantli
sever
exacerb
occur
patient
gg
genotyp
compar
patient
tt
tg
genotyp
vs
respect
chisquar
p
genotyp
signific
effect
mortal
p
signific
associ
mmrc
gg
genotyp
patient
gg
genotyp
mmrc
median
compar
patient
tt
tg
genotyp
tabl
chisquar
p
although
differ
unadjust
charlson
score
p
suggest
similar
distribut
comorbid
life
expect
group
five
time
number
patient
gg
genotyp
diagnos
malign
start
studi
compar
patient
tt
tg
genotyp
chisquar
p
associ
gg
genotyp
malign
remain
adjust
age
smoke
p
mannwhitneyutest
show
signific
differ
gg
genotyp
tttg
genotyp
tabl
genotyp
effect
mortal
p
exacerb
rate
p
time
exacerb
p
cc
genotyp
associ
bode
index
patient
bode
index
median
compar
patient
tc
patient
tt
genotyp
p
circul
detect
copd
patient
stabl
phase
copd
patient
exacerb
phase
wherea
detect
blood
sampl
healthi
control
level
higher
control
compar
copd
patient
stabl
phase
exacerb
phase
followup
exacerb
fig
associ
chisquar
test
p
genotyp
chisquar
test
p
whether
detect
stabl
phase
none
patient
gold
iv
classif
detect
circul
stabl
phase
patient
classifi
gold
iii
patient
classifi
gold
ii
detect
circul
level
gold
ii
pgml
rang
undetect
gold
iii
pgml
rang
undetect
patient
similar
level
circul
less
healthi
control
pgml
iqr
use
mannwhitneyutest
patient
detect
circul
significantli
better
postbronchodil
predict
patient
undetect
vs
p
found
signific
correl
circul
post
bronchodil
predict
spearman
rho
p
signific
differ
variabl
includ
qualiti
life
patient
detect
circul
patient
nondetect
circul
signific
associ
circul
linear
regress
beta
ci
p
associ
patient
detect
circul
significantli
patient
undetect
level
mannwhitney
utest
median
iqr
vs
iqr
ngml
respect
p
signific
differ
collagen
biomark
two
group
patient
viral
infect
thought
play
role
exacerb
copd
member
interferon
lambda
famili
immunemodulatori
antitumorigen
effect
induc
viral
infect
first
studi
evalu
associ
ifnl
circul
level
polymorph
patient
copd
distribut
snp
adher
hardi
weinberg
equilibrium
ethnic
background
strongli
impact
snp
distribut
howev
peopl
caucasian
ancestri
main
ethnic
background
present
cohort
balanc
distribut
genet
polymorph
copd
cohort
snp
gg
genotyp
significantli
influenc
sever
exacerb
rate
time
sever
exacerb
associ
higher
mmrc
score
convers
snp
effect
exacerb
death
line
known
hepat
diabet
snp
gg
genotyp
consid
risk
genotyp
snp
cc
genotyp
protect
genotyp
polymorph
predict
respons
treatment
patient
hepat
c
found
preval
malign
increas
among
patient
gg
genotyp
also
seen
patient
chronic
hepat
c
patient
gg
nontt
genotyp
hepatocellular
carcinoma
antiretroviraltr
hivinfect
patient
howev
snp
cc
genotyp
associ
higher
mortal
thu
protect
copd
patient
found
snp
cc
genotyp
associ
higher
bode
index
thu
possibl
higher
risk
mortal
though
cc
genotyp
associ
mortal
directli
studi
found
associ
genotyp
circul
level
literatur
associ
genotyp
circul
level
vari
accord
ill
group
arpaci
et
al
found
associ
genotyp
circul
patient
hashimoto
thyroid
langhan
et
al
found
hepat
c
patient
protect
snp
cc
genotyp
circul
compar
patient
snp
tt
genotyp
wherea
alborzi
et
al
found
associ
circul
genotyp
less
secret
primari
cell
asthmat
patient
compar
cell
healthi
control
infect
viru
basal
level
similar
two
group
bullen
et
al
found
increas
basal
mrna
sputum
asthmat
patient
compar
control
thu
far
literatur
regard
basal
serum
level
asthma
patient
compar
control
circul
level
similar
hepat
c
patient
healthi
control
arpaci
et
al
found
increas
basal
circul
patient
hashimoto
thyroid
compar
healthi
control
cohort
copd
patient
basal
circul
level
significantli
less
compar
control
circul
level
increas
exacerb
also
seen
vitro
cell
asthmat
patient
infect
viru
return
basal
level
patient
recov
exacerb
copd
basal
circul
level
associ
sever
airflow
limit
hypothesis
differ
circul
healthi
donor
gold
ii
gold
iii
gold
iv
patient
may
due
associ
also
due
remodel
extracellular
matrix
lung
hypothesi
part
corrobor
fact
strong
associ
circul
nproteas
cleavag
site
type
iii
collagen
marker
tissu
format
low
level
associ
wors
lung
function
shorter
time
sever
exacerb
therefor
possibl
chang
cell
structur
lung
result
decreas
secret
caus
impair
immun
respons
infect
exacerb
occur
result
remodel
cell
less
secret
associ
impair
lung
function
viciou
cycl
continu
also
possibl
decreas
circul
facilit
viral
infect
lead
less
result
wors
lung
function
shorter
time
exacerb
unabl
determin
element
catalyst
therefor
studi
requir
explor
associ
polymorph
remodel
extracellular
matrix
stabl
exacerb
copd
found
associ
circul
level
diseas
outcom
also
evid
patient
hepat
c
main
limit
studi
genotyp
result
healthi
control
snp
data
valid
separ
cohort
investig
two
snp
studi
need
investig
snp
relat
addit
circul
measur
unmatch
blood
donor
sampl
howev
found
associ
circul
level
gender
age
differ
seen
healthi
control
copd
patient
probabl
due
gender
age
differ
clinic
valu
alon
combin
biomark
assess
conform
random
clinic
trial
strength
studi
includ
origin
longitudin
design
assess
clinic
relev
endpoint
fact
genotyp
circul
determin
larg
multicentr
cohort
polymorph
may
play
role
diseas
activ
outcom
copd
circul
may
associ
diseas
sever
stabil
investig
requir
determin
underli
mechan
